NCT06208878
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Enrolling by Invitation
Not specifiedAges 18+ObservationalCRISPR Therapeutics AG
~70 participants
Updated 2025-08-14 on ClinicalTrials.gov
What's tested:Non Interventional
At a glance
Recruiting sites
0 of 22 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
Measured over 15 years
Conditions
Where it's being run
22 sites across 17 statesCalifornia3
Texas3
New York2
Connecticut1
Georgia1
Illinois1
Kansas1
Minnesota1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
Must have received CRISPR CAR T cellular therapy.
What this trial measures
- The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.15 years
The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized.